Rivus Pharmaceuticals

Rivus Pharmaceuticals is focused on advancing cardiometabolic health by developing new oral medicines from its proprietary development platform. Its lead therapy HU6 is a potential best-in-class oral MASH therapy, advancing in the ongoing AMPLIFY Phase 2 trial for MASH. The pipeline also includes RV-8451, a highly-differentiated oral GLP-1, in IND-enabling studies for obesity.

Rivus Pharmaceuticals is a company in Charlottesville, United States. It is focused on advancing cardiometabolic health by developing new oral medicines from its proprietary development platform. Its lead therapy HU6 is a potential best-in-class oral MASH therapy, advancing in the ongoing AMPLIFY Phase 2 trial for MASH. The pipeline also includes RV-8451, a highly-differentiated oral GLP-1, in IND-enabling studies for obesity.

• HU6

  Potential best-in-class oral MASH therapy, advancing in the ongoing AMPLIFY Phase 2 trial for MASH.

• RV-8451

  Highly-differentiated oral GLP-1, in IND-enabling studies for obesity.

1. Rivus Pharmaceuticals
2. About | Management | Board of Director | Investors | Rivus Pharmaceuticals
3. Rivus Pharmaceuticals, Inc. (United States)